

## **Innovations in Transdermal Drug Delivery: Strategies, Challenges and Future Directions**

**Dhanshri Mahajan, Akash Yadav\*, Dinesh Kumar Jain**

*IPS Academy College of Pharmacy, Knowledge Village, Rajendra Nagar, A.B. Road, Indore-452012*

Received: 20-02-2024 / Revised: 29-02-2024 / Accepted: 10-03-2024

Corresponding Author: Dr. Akash Yadav

Email: [akashyadav@ipsacademy.org](mailto:akashyadav@ipsacademy.org)

Conflict of interest: Nil

### **Abstract:**

Transdermal drug delivery systems offer an efficient and non-invasive means of administering therapeutic agents through the skin for systemic distribution. This approach bypasses the gastrointestinal tract, avoiding issues such as enzymatic degradation and first-pass metabolism, while offering sustained release and improved patient compliance. The skin's barrier properties, primarily the stratum corneum, present challenges for effective drug penetration, requiring the use of various enhancement strategies like chemical penetration enhancers, physical methods (e.g., iontophoresis, microneedles), and formulation technologies (e.g., nanoparticles, liposomes). Key factors influencing transdermal delivery include drug physicochemical properties, formulation design, and skin characteristics. Advancements in formulation technologies, coupled with an improved understanding of skin physiology and drug permeation mechanisms, continue to expand the application of transdermal delivery across various therapeutic areas, offering promising avenues for personalized medicine and enhanced patient care.

**Keywords:** *TDDS, Strategies, Components, Functions, Systems*

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

### **Introduction:**

Transdermal drug delivery systems (TDDS), sometimes referred to as patches, are dosage forms intended to distribute a therapeutically effective quantity of medication across a patient's skin. To administer therapeutic drugs for systemic effects via the human skin, it is necessary to take into account the skin's comprehensive morphological, biophysical, and physicochemical features. When compared to the previous two decades, advancements in the field of drug delivery are happening far more quickly. Two essential components of novel drug delivery systems are increased patient compliance and efficacy. [1] Investigating more recent bodily interfaces for the introduction of treatments has shown to be a more radical strategy. Transdermal drug delivery is one such method that uses the human skin as a point of entry for the systemic distribution of medication molecules.[2] One of the methods falling under the category of controlled drug delivery is the transdermal drug delivery system (TDDS), whose goal is to distribute the drug via the skin at a predetermined and regulated pace. TDDS are sticky, drug-containing devices with a specific surface area that release a dose of medication into undamaged skin at a predetermined rate in order to enter the bloodstream.[3] Because transdermal distribution avoids initial metabolism and increases patient compliance, it offers a significant advantage over injectables and oral routes.[4] The transdermal route has been in competition with oral treatment to be the most successful innovative research area in drug delivery. This is because oral treatment involves introducing a fixed dose at regular intervals to maintain the drug concentration in the body within a therapeutically effective range, which increases the risk of side effects or therapeutic failure. Additionally, a significant amount of drug is lost in the vicinity of the target organ, necessitating close monitoring of therapy to prevent overdosing.[5] Transdermal drug administration through intact skin can closely mimic the benefits of intravenous drug infusion, without the potential risks, and overcome the limitations of the oral route. This includes the ability to avoid hepatic "first pass" hepatic elimination (HEPE) and maintain constant, prolonged, and therapeutic effective drug levels in the body.[6] Transdermal delivery offers a significant advantage over oral and injectable methods due to its ability to prevent first-pass metabolism and increase patient compliance, respectively.[7] Transdermal delivery prevents pulsed

entry into systemic circulation, which frequently results in undesired side effects, and permits continuous input of medications with short biological half-lives. It also offers regulated, continuous drug administration. Therefore, there are many different types of novel drug delivery methods, like transdermal, controlled-release, and transmucosal administration systems.[8]

### **Physiology of the Skin:**

#### **Structure of the skin:**

The skin is the largest organ of the human body and is composed of three primary layers: the epidermis, the dermis, and the subcutaneous tissue (also known as the hypodermis).

- **Epidermis:**

The skin's outermost layer, the epidermis, acts as a barrier to keep out viruses, UV rays, and environmental influences. It is mainly made up of keratinocytes, which provide the skin its structural strength by producing the keratin protein. Melanocytes, which produce the pigment melanin and aid in UV damage protection, are also found in the epidermis.

- a) **Stratum Corneum:** The outermost layer of the epidermis is made up of flattened, dead keratinocytes known as corneocytes. Because of the lipid matrix in which these cells are attached, the body is shielded from environmental stressors and excessive water loss is curbed.
- b) **Stratum Lucidum:** This translucent layer, which is only seen in thick skin (such as the palms and soles), is made up of keratinocytes that are closely spaced and have a high concentration of keratin fibers.
- c) **Stratum Granulosum:** The stratum granulosum, which lies beneath the stratum corneum, is home to granular keratinocytes that generate keratohyalin granules, which help the skin become waterproof and make keratin fibres.
- d) **Stratum Spinosum:** The stratum spinosum is made up of many layers of keratinocytes with polygonal shapes joined by desmosomes, which give the epidermis structural integrity and support. Cell differentiation and division are processes involving this layer.
- e) **Stratum Basale (Stratum Germinativum):** Basal cells are found in the stratum basal, the lowest layer of the epidermis. These cells constantly divide and migrate upward to replenish the top layers of the epidermis. Merkel cells, which are involved in touch perception, and melanocytes, which generate the pigment melanin responsible for skin colour, are also found in this layer.

**Dermis:** Beneath the epidermis is the dermis, which is made up of collagen and elastin fibre-containing connective tissue. It contains a variety of tissues, including sweat glands, hair follicles, nerve endings, and blood arteries. In addition to giving the skin structural support, the dermis controls the skin's temperature, sensibility, and nutrient supply to the epidermis.

- a) **Papillary Dermis:** The loose connective tissue that contains collagen and elastin fibres makes up the papillary dermis, which is located directly under the epidermis. Dermal papillae, which resemble fingers and are formed by this layer, interlock with epidermal ridges to strengthen the bond between the two layers and promote nutrition exchange.
- b) **Reticular Dermis:** Larger bundles of collagen and elastin fibres are found in the dense, irregular connective tissue that makes up the reticular dermis, which is located deeper in the dermis. This layer, which also includes blood, lymphatic, nerve, hair follicle, and sweat glands, gives the skin structural stability and suppleness.

**Subcutaneous Tissue (Hypodermis):** The deepest layer of the skin is called the subcutaneous tissue (hypodermis), which is made up of loose connective tissue and adipose (fat) tissue. It serves as a layer of cushioning, offering energy storage, shock absorption, and insulation. Blood vessels and nerves that supply the skin and underlying tissues are also found in the hypodermis. The subcutaneous layer, or hypodermis, include nerves, blood vessels, and adipose tissue. It connects the skin to the underlying tissues and serves as a cushion, insulator, and energy reservoir. It also provides support and controls temperature.[9]




Fig. 1: Structure of Skin

### Functions of Skin:

**Protection:** The skin serves as a physical barrier, shielding the body from toxins, infections, and physical trauma. With its protective keratin covering on the outside, the epidermis is an important barrier against environmental stresses and a major factor in limiting water loss.

- **Thermoregulation:** By dilation to release heat and constriction to retain heat, blood vessels in the dermis aid in controlling body temperature. When the body temperature rises, perspiration produced by the skin's sweat glands evaporates from the skin's surface, helping to cool the body.[10]
- **Sensation:** Touch, pressure, temperature, and pain are just a few of the stimuli that are detected by specialized nerve endings in the skin that allow us to perceive feelings and environmental cues.
- **Excretion:** The skin's sweat glands help the body detoxify by excreting waste materials such as urea, electrolytes, and poisons.
- **Absorption:** Even though the skin's main purpose is to act as a barrier, some chemicals can pass through it and enter the bloodstream. Transdermal drug delivery systems use this characteristic to apply medicine topically.[11]

### Barrier Properties of the Skin:

The stratum corneum—a layer of dead, flattened keratinocytes embedded in a lipid matrix—acts as the main barrier to substances entering and leaving the body and makes up the majority of the skin barrier, which is made up of several layers within the epidermis.

- **Stratum Corneum:** Keratinocytes and lipids are tightly packed into this topmost layer of the epidermis to form a hydrophobic barrier that minimizes water loss from the body and blocks the entry of pathogens and water-soluble substances.
- **Lipid Barrier:** The stratum corneum contains lipids that are essential for preserving the integrity and hydration of the skin, including ceramides, cholesterol, and fatty acids. A breach in the lipid barrier may result in heightened permeability and vulnerability to allergens and irritants
- **Tight Junctions:** In the stratum corneum, tight connections between keratinocytes offer extra microbial resistance, enhancing the skin's overall barrier function.[12]

### Mechanisms of Transdermal Drug Delivery:

- **Passive Diffusion:** The majority of medicines cross the epidermal barrier mostly by passive diffusion. Without the use of energy, chemicals are moved from a region of higher concentration—the formulation—to a region of lower concentration the skin layers. The primary impediment to medication penetration is the stratum corneum's lipid-rich matrix. While bigger or hydrophilic molecules may face barriers or have slower diffusion rates, smaller, lipophilic molecules can diffuse through the intercellular lipid bilayers.[13]

- **Active Transport:** Molecules are transported against their concentration gradient by active transport processes, which need energy. Active transport is less frequently used in transdermal drug administration than passive diffusion, although it can be used for some medications or endogenous substances that need particular carrier proteins or ion pumps to help them pass through the skin barrier. A few instances are the movement of peptides or amino acids through certain transporter proteins found in the layers of the skin.[14]
- **Facilitated Transport:** Transport via carrier proteins or channels facilitates the passage of molecules over the epidermal barrier. This process is sometimes referred to as carrier-mediated transport. Facilitated transport depends on concentration gradients and certain binding interactions between the molecule and the carrier, but it does not require energy input like active transport does. This mechanism is especially important for compounds that can bind to certain transporters or channels to help them transit through the layers of the skin but are too big or polar to diffuse passively across the lipid bilayers.[15]
- **Other Mechanisms (e.g., Iontophoresis):** To improve transdermal medication delivery, other mechanisms can be used in addition to passive diffusion, active transport, and facilitated transport. By applying a small electrical current to the skin, iontophoresis allows charged molecules—like ions or ionized medications—to pass past the epidermal barrier through electroosmosis or electro repulsion. This method works well for delivering ionizable chemicals and can improve the penetration of some medications.[16]

#### **Components of Transdermal Drug Delivery System:**

- **Drug Formulation:**

##### **Active Pharmaceutical Ingredient (API):**

The primary medicinal ingredient meant to be applied topically is called the API. It is the active component in the mixture that gives rise to the intended pharmacological action.

##### **Excipients:**

Excipients are inert components added to the medication formulation to improve the transdermal delivery system's overall performance, stability, solubility, and permeability. Preservatives, antioxidants, gelling agents, penetration enhancers, and solvents are a few examples of these.[17]

#### **Delivery System Components:**

- a) **Matrix or Reservoir:** The main means of enclosing and dispensing the medication formulation onto the skin is the matrix or reservoir. The drug formulation in a matrix system is distributed throughout a polymer matrix, which releases the medication gradually over time. A membrane that regulates drug release keeps the drug formulation inside a drug reservoir and keeps it isolated from the skin in a reservoir system.
- b) **Adhesive Layer:** The transdermal patch is attached to the skin's surface via the adhesive layer. It guarantees appropriate skin-to-patch contact, reducing drug leakage and promoting consistent drug delivery. Pressure-sensitive adhesives (PSAs), which offer strong adherence without irritating the skin, are commonly utilized in transdermal patches.
- c) **Backing Layer:** The transdermal patch's backing layer gives it structural support and shields the medication formulation from environmental impurities, moisture, and physical harm. Usually composed of materials that are impermeable, like polyester or polyethylene, it guarantees that the medicine will only be released through the specific area of skin contact.
- d) **Release Liner:** Before being applied, the release liner forms a barrier over the transdermal patch's sticky surface. In order to reveal the adhesive layer and make it easier for the patch to adhere to the skin, it is removed before application. Usually composed of silicone-coated materials, release liners allow simple removal of the adhesive without leaving residue on the patch and stop it from sticking too soon.[18]

#### **Factors Affecting Transdermal Drug Delivery:**

##### **1. Physicochemical properties of the drug:**

- a) **Molecular Size:** Compared to bigger molecules, smaller molecules can pass through the skin's barrier more easily. This is a result of smaller molecules' improved ability to move across the stratum corneum's intercellular gaps.

- b) **Lipophilicity:** Drugs that are lipophilic, or fat-soluble, are more likely to pass through the stratum corneum, which is lipid-rich. On the other hand, because the stratum corneum is hydrophobic, medications that are hydrophilic (water soluble) may encounter more resistance.
  - c) **Ionization:** A medication's capacity to penetrate skin is influenced by its ionization state. Drugs that aren't ionized typically penetrate the skin more easily because they can more easily cross the lipid barrier. Ionized forms, however, might find it harder to penetrate because of their charge.
  - d) **Partition Coefficient:** Drugs with a high partition coefficient (lipophilic drugs) tend to permeate the skin more easily than those with a low partition coefficient (hydrophilic drugs), which may provide more challenges. This is the ratio of a drug's solubility in lipids to water.
- 2. Skin characteristics:**
- a) **Thickness:** varied parts of the body have varied skin thicknesses. In general, thinner regions—like the face and genitalia—allow for better medication absorption than thicker regions—like the palms and soles.
  - b) **Integrity:** Skin that is in good health poses a significant obstacle to the entry of drugs. Skin that is ill or damaged, such as eczema or psoriasis, may have a weakened skin barrier, which increases the absorption of drugs.
  - c) **Vascularity:** Higher vascularity areas of the body, such as the face or scalp, may absorb medications more quickly because of increased blood flow, which makes it easier for pharmaceuticals to be transported away from the application site.
  - d) **Hair Follicles:** Particularly for lipophilic medicines, which can build up in the follicular reservoirs and then enter the systemic circulation, hair follicles can serve as passageways for drug penetration.[19]
- 3. Formulation factors:**
- a) **Vehicle composition:** The medication release and penetration are impacted by the type of vehicle (gel, cream, patch, etc.). Because lipid-based carriers solubilize lipophilic medications, they may improve drug penetration.
  - b) **Penetration enhancers:** Chemicals that alter the structure of the stratum corneum, such as alcohols, fatty acids, and surfactants, can make skin more permeable.
  - c) **Excipients:** The release kinetics, skin compatibility, and stability of the medicine can all be impacted by additional components in the formulation.
- 4. Application site:**
- a) **Skin anatomy:** Drug absorption rates are influenced by variations in skin thickness, vascularity, and hair follicle density among various body regions.
  - b) **Blood flow:** Higher blood flow regions, like the scalp or forearms, may show faster drug absorption because of improved drug delivery into the bloodstream.
- 5. Environmental factors:**
- a) **Temperature and humidity:** Temperature and humidity variations can affect skin moisture and permeability, which can affect how quickly drugs are absorbed.
  - b) **Sunlight exposure:** UV light can alter the metabolism and integrity of the skin, which may have an impact on how well drugs are absorbed.
  - c) **Sweat and physical activity:** Exercise and sweating can enhance blood flow and skin moisture, which can impact how well drugs are delivered through the skin.[20]

### **Types of Transdermal Drug Delivery Systems:**

#### **Matrix Systems:**

A homogenous matrix with the medicine distributed throughout an adhesive or polymer matrix is what defines matrix systems. Diffusion via the matrix material is the primary mechanism that regulates drug release from matrix systems. This diffusion-based release mechanism makes it possible to distribute drugs continuously for a long time.[21]




Fig.1 Matrix System

**Reservoir Systems:**

A drug reservoir is positioned between a backing layer and a rate-controlling membrane in reservoir systems. The drug suspension or solution is contained in the drug reservoir, and its release is regulated by the rate-controlling membrane. Drug release from reservoir systems can occur through diffusion or osmotic pressure across the membrane. Drugs with controlled release patterns are frequently delivered using these devices.[22]




Fig.3 Reservoir System

**Drug-in-Adhesive Systems:**

In drug-in-adhesive systems, the medication is dispensed into an adhesive layer that comes into direct contact with the skin. In addition to securing the patch to the skin, the sticky coating promotes medication penetration and release. The main way that drugs are released is by diffusion through the layer. Convenience and application simplicity are features of these systems.[23]




Fig.4 Drug in Adhesive System

**Matrix-Reservoir Hybrid Systems:**

The characteristics of matrix and reservoir systems are combined in matrix-reservoir hybrid systems. These systems usually consist of a matrix or sticky layer around a reservoir that holds drugs. Adhesion to the skin and

control over medication release are provided by the matrix or sticky layer. Good skin contact is maintained while regulated release kinetics are possible thanks to its design.[24]

#### **Microstructure Transdermal Systems:**

To improve drug delivery, microstructure systems use tiny protrusions called microneedles. By piercing the stratum corneum, these microneedles provide temporary drug delivery channels. Depending on the needs of the particular application, microneedles can be coated, hollow, solid, or dissolvable. They have benefits including better medication penetration and painless administration.[25]

#### **Formulation Strategies:**

- a) **Enhancement of Drug Permeation:** In order to more successfully reach their target site of action, this technique entails improving the medications' ability to cross biological barriers, such as the skin, mucosal membranes, or cell membranes. To improve medication penetration, a number of strategies can be used, including. Making use of penetration enhancers These are substances that have the ability to interfere with the membrane's barrier function, making it easier for medications to pass through. By applying nanotechnology, pharmaceuticals can be encapsulated and transported across biological barriers more easily with the help of nanoparticles. Lipid-based formulations: By interacting with cell membranes and encouraging medication uptake, lipid-based carriers such as liposomes or nano emulsions can enhance drug penetration. Prodrug design: Drugs can penetrate biological barriers more easily if they are chemically modified to increase their lipophilicity or stability.
- b) **Modulation of Drug Release:** In order to maintain therapeutic drug levels and minimize adverse effects, this method entails regulating the rate and duration of drug release from the dosage form. There are several methods for adjusting medication release, such as. Creating formulations with prolonged release: These formulations allow for less frequent dosage and better patient compliance by releasing the medication gradually over an extended period of time. Making use of matrix systems In matrix systems, the drug is evenly distributed within a matrix that controls its rate of release by mechanisms such as erosion or diffusion. Using layered or coated formulations: The release kinetics of the medicine can be regulated by coating it with a polymer layer; mucoadhesive coatings for sustained release at particular places, or enteric coatings for delayed release.
- c) **Combination Therapies:** Combination therapies include giving two or more medications at the same time in an effort to overcome drug resistance, increase efficacy, or produce synergistic effects. Combination therapy formulation techniques could involve the following. Co-formulating medications in a single dosage form: This approach improves patient compliance by streamlining dosage schedules and combining several medications into one formulation. creating medications with supplementary modes of action: Drug combinations that target Co-delivering numerous medications via drug delivery systems: Different drugs can be encapsulated and delivered to the target site concurrently using liposomes, polymer conjugates, or nanoparticles, ensuring co-localization both temporally and spatially.
- d) **Use of Permeation Enhancers:** Enhancers of permeability are substances that facilitate the passage of medications through biological barriers, such endothelium or epithelial membranes. These enhancers have a variety of modes of action, including. Lipid bilayer disruption: A few surfactants or bile salts have the ability to cause cell membrane structure to break down, which increases membrane fluidity and makes it easier for drugs to pass through. Improving paracellular transport: Substances that temporarily open intercellular tight junctions, such as chelating agents or tight junction modulators, enable medications to flow through cell gaps. Blocking efflux transporters: P-glycoprotein is one efflux transporter that can pump medications out of cells, lowering their intracellular concentration. By blocking these transporters, permeability enhancers can extend the time that drugs remain in cells. Changing physiological conditions: By altering the local microenvironment and changing fluid dynamics or membrane permeability, pH modifiers and osmotic agents can improve medication penetration.[26]

#### **Future Perspectives and Challenges:**

**Emerging technologies:** Treatments could be revolutionized by developing technologies. Gene editing promises customized therapeutics, whereas nanotechnology allows for precise medication targeting. Customized dosage forms can be produced on demand using 3D printing, and intelligent drug delivery systems provide controlled

release and real-time monitoring. Resolving issues like sustainability, biocompatibility, and legal barriers is critical to achieving the full potential of these breakthroughs in improving patient care and filling global gaps in medicine.[27]

**Addressing limitations and challenges:** In order to assure safe, efficient, and easily accessible medicines, addressing constraints and hurdles in medication delivery in the future requires overcoming a variety of complex impediments. Innovative materials and formulations that reduce adverse responses and improve patient tolerance are developed in response to biocompatibility problems. The search for environmentally friendly production techniques and biodegradable delivery methods is motivated by sustainability imperatives in an effort to reduce environmental effect. Stakeholders must work transparently together to overcome regulatory obstacles in order to expedite approval procedures and maintain strict safety standards. To fulfil the transformational potential of improved drug delivery technologies, overcoming these obstacles requires multidisciplinary collaboration, vigorous research efforts, and a dedication to striking a balance between innovation and safety and accessibility.[28]

**Potential advancements in transdermal drug delivery:** Though they confront many obstacles, potential breakthroughs in transdermal drug delivery hold the potential to transform treatment approaches. Smart patches, nanotechnology, and microneedles are examples of cutting-edge technologies that provide better patient compliance and targeted medication delivery. Nevertheless, issues with dose accuracy, regulatory approval, and skin barrier penetration continue to exist. To overcome these challenges, formulation tactics must be improved, delivery systems must be optimized, and safety concerns must be addressed. Furthermore, there is potential for tailored transdermal medicines and integration with digital health platforms; nevertheless, in order to guarantee safety and efficacy in clinical settings, thorough validation and regulatory guidance are required. While tackling these obstacles, cooperation between academic institutions, business, and regulatory bodies is crucial to realizing transdermal drug delivery's full potential.[29]

#### **Conclusion:**

Transdermal drug delivery systems offer a non-invasive and convenient approach to administering medications, bypassing issues associated with oral delivery and injections. By utilizing the skin as a route of administration, these systems provide advantages such as sustained release, improved patient compliance, and reduced side effects. However, challenges including skin barrier penetration and regulatory requirements remain. Future advancements in nanotechnology, personalized therapies, and integration with digital health platforms hold promise for overcoming these challenges and expanding the applications of transdermal drug delivery. Collaborative efforts between stakeholders are essential to harness the full potential of these innovations for enhancing patient care and addressing unmet medical needs.

#### **References:**

1. Tiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: formulations and techniques. *Recent patents on drug delivery & formulation*. 2007 February:23-36.
2. Singh A, Singh MP, Alam G, Patel R, Vishvakarma D, Datt N. Expanding opportunities for transdermal delivery systems: An overview. *Journal of Pharmaceutical research* 2011 May:17-20.
3. Patel H, Patel U, Bhimani B, Daslaniya D. Transdermal drug delivery system as prominent dosage forms for the highly lipophilic drugs. *The International Journal of Pharmaceutical Research and Bio-Science*. 2012 January:13-15.
4. Kumar JA, Pullakandam N, Prabu SL, Gopal V. Transdermal drug delivery system: an overview. *Journal of pharmaceutical research* 2010 July:49-54.
5. Jain NK, editor. *Advances in controlled and novel drug delivery*. CBS publishers & distributors; 2011 May: 69-71.
6. Soni M, Kumar S, Gupta GD. Transdermal drug delivery: A novel approach to skin permeation. *Journal of pharmaceutical research* 2009 January:84-90.
7. Allen Jr LV. *Pharmaceutical Dosage Forms and Drug Delivery Systems*. 2015 March:33-37.



8. Kumar P, Sankar C, Mishra B. Delivery of macromolecules through skin. *The Indian Pharmacist*. 2019 March:7-18.
9. Ali S, Shabbir M, Shahid N. The structure of skin and transdermal drug delivery system-a review. *Research journal of pharmacy and technology* 2015 August :3-9.
10. Montagna W. The structure and function of skin. Elsevier; 2012 December 2-4.
11. Eyerich S, Eyerich K, Traidl-Hoffmann C, Biedermann T. Cutaneous barriers and skin immunity: differentiating a connected network. *Trends in immunology*. 2018 April:15-27.
12. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. *European journal of pharmaceutical sciences*. 2017 September:1-14.
13. Ghulaxe C, Verma R. A review on transdermal drug delivery system. *The Pharma Innovation*. 2015 March 37-39.
14. Dancik Y, Thompson C, Krishnan G, Roberts MS. Cutaneous metabolism and active transport in transdermal drug delivery. *Toxicology of the Skin*. 2010 February:83-96.
15. Prausnitz MR, Elias PM, Franz TJ, Schmuth M, Tsai JC, Menon GK, Holleran WM, Feingold KR. Skin barrier and transdermal drug delivery *Dermatology* 2012 March:65-73.
16. Wang Y, Thakur R, Fan Q, Michniak B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. *European Journal of Pharmaceutics and Biopharmaceutics*. 2005 July:79-91.
17. Ramteke KH, Dhole SN, Patil SV. Transdermal drug delivery system: a review. *Journal of Advanced Scientific Research*. 2012 February:22-35.
18. Yadav V. Transdermal drug delivery system. *International journal of pharmaceutical sciences and research*. 2012 February:376.
19. Sudam KR, Suresh BR. A Comprehensive Review on: Transdermal drug delivery systems. *International Journal of Biomedical and Advance Research* 2016 July:47-59.
20. Mishra DK, Pandey V, Maheshwari R, Ghode P, Tekade RK. Cutaneous and transdermal drug delivery: Techniques and delivery systems. In *Basic Fundamentals of Drug Delivery* 2019 January 1-5.
21. Aqil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol tartrate: In vitro characterization. *Acta Pharmaceutica Zagreb* 2003 June:19-26.
22. Prodduturi S, Smith GJ, Wokovich AM, Doub WH, Westenberger BJ, Buhse L. Reservoir based fentanyl transdermal drug delivery systems: effect of patch age on drug release and skin permeation. *Pharmaceutical research*. 2011 June:44-52.
23. Hafeez A, Jain U, Singh J, Maurya A, Rana L. Recent advances in transdermal drug delivery system (TDDS): an overview *Journal of Scientific and Innovative Research* 2013 February:33-44.
24. Ahmed A. *International Journal of Biomedical and Advance Research* 2014 January 1112-1117.
25. Lapteva M, Kalia YN. Microstructured continuous phase formulations: their characterization and application in dermal and transdermal drug delivery. *Expert opinion on drug delivery*. 2013 August:43-59.
26. Ham AS, Buckheit Jr RW. Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors. *Therapeutic delivery* 2015 February:17-29.
27. Qindeel M, Ullah MH, Ahmed N. Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy. *Journal of Controlled Release*. 2020 November:595-615.
28. Tapfumaneyi P, Imran M, Mohammed Y, Roberts MS. Recent advances and future prospective of topical and transdermal delivery systems. *Frontiers in Drug Delivery*. 2022 September 6570-6577.
29. Nishitani Yukuyama M, Tomiko Myiake Kato E, Lobenberg R, Araci Bou-Chacra N. Challenges and future prospects of nanoemulsion as a drug delivery system. *Current pharmaceutical design*. 2017 January:495-508.